MRP expression in acute myeloid leukemia: An update

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 141-150

  Filipits, Martin ^a   Stranzl, Thomas ^a   Pohl, Gudrun ^a   Suchomel, Ralf W ^a   Zöchbauer, Sabine ^a   Brunner, Raoul ^a   Lechner, Klaus ^a   Pirker, Robert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acute myeloid leukemia; Drug resistance; MRP; Multidrug resistance; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; KARYOTYPING; MALE; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANCE; PATHOLOGY; REMISSION; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; P-GLYCOPROTEIN; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0032612979     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_16     Document Type: Article

References (30)

1. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H and Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991, 83, 708-712
2. Marie J-P, Zittoun R and Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991, 78, 586-592
3. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D and Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992, 79, 473-476
4. Zöchbauer S, Gsur A, Brunner R, Kyrle PA, Lechner K and Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994, 8, 974-977
5. Simon SM and Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994, 91, 3497-3504
6. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654
7. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC and Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994, 54, 357-361
8. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM and Deeley RG. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994, 54, 5902-5910
9. Filipits M, Suchomel RW, Zöchbauer S, Brunner R, Lechner K and Pirker R. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin Cancer Res 1997, 3, 1419-1425
10. Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D and Pirker R. MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 1996, 2, 1231-1237
11. r 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 1994, 54, 5788-5792
12. Kaplan EL and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481
13. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG and Metha AB. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia 1994, 8: 2163-2168
14. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ and Kaufmann SH. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995, 85, 186-193
15. Zhou D-C, Zittoun R and Marie J-P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995, 9, 1661-1666
16. Ross DD, Doyle LA, Schiffer CA, Lee EJ, Grant CE, Cole SPC, Deeley RG, Yang W and Tong Y. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Leukemia 1996, 10, 48-55
17. Burger H, Nooter K, Zaman GJR, Sonneveld P, van Wingerden KE, Oostrum RG and Stoter G. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 1994, 8, 990-997
18. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Baak JPA, Eekman CA, Kuiper CM, Feller N, van Heijningen THM, Klumper E, Pieters R, Lankelma J and Pinedo HM. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1995, 1, 81-93
19. Nooter K, Westerman AM, Flens MJ, Zaman GJR, Scheper RJ, van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P, Gratama JW, Kok T, Eggermont AMM, Bosman FT and Stoter G. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995, 1, 1301-1310
20. Legrand O, Perrot J-Y, Tang RP, Simonin G, Gurbuxani S, Zittoun R and Marie J-P. Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. Br J Haematol 1996, 94, 23-33
21. Kuss BJ, Deeley RG, Cole SPC, Willman CL, Kopecky KJ, Wolman SR, Eyre HJ, Lane SA, Nancarrow JK, Whitmore SA and Gallen DF. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet 1994, 343, 1531-1534
22. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL and Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996, 334, 231-238
23. Filipits M, Malayeri R, Suchomel RW, Pohl G, Stranzl T, Dekan G, Kaider A, Stiglbauer W, Depisch D and Pirker R. Multidrug resistance protein (MRP) is an independent prognostic factor in breast cancer. Submitted
24. Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T, Tamaoki N and Nakamura M. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 1995, 72, 550-554
25. Izquierdo MA, van de Zee AGJ, Vermorken JB, van der Valk P, Belien JAM, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJLM, de Vries EGE and Scheper RJ. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995, 87, 1230-1237
26. Filipits M, Suchornel RW, Dekan G, Stiglbauer W, Haider K, Depisch D and Pirker R. Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas. Br J Cancer 1997, 75, 208-212
27. Filipits M, Suchomel RW, Zöchbauer S, Malayeri R and Pirker R. Clinical relevance of drug resistance genes in malignant diseases. Leukemia 1996, 10, Suppl. 3, 10-17
28. Malayeri R, Filipits M, Suchomel RW, Zöchbauer S, Lechner K and Pirker R. Multidrug resistance in leukemias and its reversal. Leuk Lymphoma 1997, 23, 451-458
29. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ and Dalton WS. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996, 87, 2464-2469
30. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geissler K, Lechner, K and Pirker R. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998, 91, 1508-1513